Close menu




Biotech

Photo credits: pixabay.com

Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST

BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus

  • Biotechnology
  • Cancer
  • Covid19

Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.

Read

Commented by Nico Popp on August 30th, 2023 | 07:00 CEST

Course Rockets of Yesterday - and Tomorrow: Innocan Pharma, BioNTech, Cardiol Therapeutics

  • Biotechnology
  • Pharma
  • Innovations

According to the information service IQVIA, dietary supplements generate almost EUR 3 billion in sales in Germany - and the trend is rising. More and more people are paying attention to their health and are not satisfied when the doctor says, "You are healthy." In fact, there is still a lot of upside potential for healthy people, too - for example, when it comes to reducing stress, improving sleep or strengthening the body's own defenses. Today, we highlight three stocks that could benefit from increased health awareness.

Read

Commented by Juliane Zielonka on August 24th, 2023 | 07:00 CEST

Defence Therapeutics, Bayer, Palantir - Milestones, Power Shifts and Mishmash

  • Biotechnology
  • Software
  • Technology

The radiopharmaceuticals market is expected to grow to USD 13.818 billion by 2028. In collaboration with Orano Group, Defence Therapeutics has developed innovative radioactive cancer therapies that destroy cancer at the cellular level, thereby increasing efficacy and minimizing side effects. According to Defence Therapeutics CEO Sebastien Plouffe, this partnership will lead to top-tier therapies in a growing market. Meanwhile, heads are rolling at Bayer, as CEO Bill Anderson has big plans and is replacing key positions with promising candidates. Employees of the British NHS have probably spoken a bit too much. The US company Palantir has been awarded five NHS contracts without competitive bidding and is currently the favorite for a multi-million dollar contract in the healthcare sector. Find out what this means for investors here.

Read

Commented by André Will-Laudien on August 23rd, 2023 | 07:00 CEST

Climate change or just a heat wave? - BioNTech, Cardiol Therapeutics, and Redcare Pharmacy deliver!

  • Biotechnology
  • Pharma

Whether this consistently warm summer already documents a pronounced climate change is questionable. The older ones among us remember that there were already very hot summers before and that even in the last 30 years, there was rarely snow at Christmas. However, human life is simply too short for significant conclusions. Therefore, long-term weather records have to be consulted. There will probably be a slight increase in average temperatures, but we will get little information about when the next ice age will hit us. For many politicians, the current weather trends fit perfectly into the chain of arguments in favor of radical legislative proposals. Perhaps, however, the caprices of the weather are only the offshoots of the approaching El Nino. The stock market also follows changing trends; after the flood, an ebb could now be imminent. Selection remains key!

Read

Commented by Stefan Feulner on August 21st, 2023 | 07:15 CEST

Meyer Burger, Saturn Oil + Gas, CureVac - Incisive events

  • Mining
  • Oil
  • Biotechnology
  • Technology

The past week in the stock market, due to the earnings season for the year's first half, brought surprises on both sides. Some companies were able to shine despite uncertainties on the economic and geopolitical side and face a golden future due to a significant undervaluation. Speaking of the future: Due to weaker market conditions, one company after another is leaving the old contingent to take advantage of better conditions overseas.

Read

Commented by Armin Schulz on August 16th, 2023 | 05:40 CEST

BioNTech, Defence Therapeutics, Bayer - Who will have trend-setting news first?

  • Biotechnology
  • Pharma

Pharmaceutical and biotech stocks are among the most volatile sectors in the financial markets. Single news stories about new developments or product announcements can not only cause short-term price swings but also have long-term implications, increasing both risk and opportunity for investors. If a breakthrough drug is developed, old preparations can become obsolete - this is good for the innovative company but detrimental to established market participants. As an investor, it is advisable to select specific companies and anticipate directional news through some research.

Read

Commented by Fabian Lorenz on August 9th, 2023 | 07:00 CEST

After BioNTech shock: Evotec, Morphosys and Cardiol Therapeutics emerge as the new biotech favorites

  • Biotechnology

BioNTech startled investors and analysts with its quarterly figures on Monday. Yet the biotech segment has actually developed positively in recent months. Several stocks are currently going full throttle, and S&P's sector index also outperformed the S&P 500 and MSCI World in July. This could finally signal the end of the underperformance of recent years, and biotech stocks could be celebrating a comeback. On the German stock charts, Evotec and Morphosys are among the high flyers. Both shares have performed strongly since April. Cardiol Therapeutics also looks promising from a technical chart perspective, and analysts see a price potential of over 200%. In contrast, there is currently no reason to buy BioNTech. Instead, investors should also bet on strength.

Read

Commented by André Will-Laudien on August 7th, 2023 | 07:55 CEST

Wild times - quarterly figures on the move! Tupperware, Defence Therapeutics, PayPal and Amazon under the magnifying glass!

  • Biotechnology
  • Software
  • Investments

After a pronounced summer rally on the stock markets, there have been individual setbacks in early August. It should come as no surprise that the reaction to quarterly figures can sometimes be more intense. Often, stocks have simply run too far and experienced a healthy consolidation; in the case of Tupperware, the opposite is probably the case. Here, too many speculators have positioned themselves on the short side, and there were hopeful reports. We analyze a few highlights of the last week.

Read

Commented by Stefan Feulner on August 2nd, 2023 | 09:15 CEST

Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi

  • Biotechnology
  • Pharma
  • AI

There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.

Read

Commented by Stefan Feulner on August 1st, 2023 | 09:00 CEST

Biogen, Cardiol Therapeutics, Evotec - The acquisition wave is rolling

  • Biotechnology
  • Pharma

The biotechnology industry has seen a significant increase in acquisitions and mergers in recent months. Large pharmaceutical companies are looking to expand their portfolios to provide innovative solutions for unmet medical needs. At the same time, despite an increase in value in recent months, acquisition targets are still attractively valued due to the sell-off over the past year.

Read